Galapagos NV (NASDAQ:GLPG) Receives $34.50 Average PT from Analysts

by · The Cerbat Gem

Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) have been given an average rating of “Hold” by the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $34.50.

A number of analysts recently issued reports on GLPG shares. StockNews.com downgraded shares of Galapagos from a “buy” rating to a “hold” rating in a report on Monday, March 18th. Morgan Stanley started coverage on shares of Galapagos in a research note on Thursday, March 7th. They set an “equal weight” rating and a $38.00 price target for the company. Finally, Bank of America reiterated an “underperform” rating and issued a $31.00 price objective (down previously from $41.00) on shares of Galapagos in a research note on Thursday, March 28th.

View Our Latest Stock Report on Galapagos

Galapagos Price Performance

Shares of Galapagos stock opened at $30.25 on Tuesday. The stock has a fifty day moving average price of $35.07 and a 200-day moving average price of $36.60. The firm has a market cap of $1.99 billion, a PE ratio of -13.21 and a beta of 0.24. Galapagos has a 1 year low of $30.24 and a 1 year high of $45.21.

Hedge Funds Weigh In On Galapagos

Several large investors have recently modified their holdings of GLPG. Segall Bryant & Hamill LLC bought a new position in Galapagos in the 1st quarter worth approximately $11,568,000. Stonepine Capital Management LLC purchased a new stake in shares of Galapagos during the fourth quarter worth $8,647,000. Point72 Asset Management L.P. boosted its holdings in shares of Galapagos by 23.1% in the second quarter. Point72 Asset Management L.P. now owns 880,668 shares of the biotechnology company’s stock worth $35,808,000 after acquiring an additional 165,068 shares during the period. BlackRock Inc. grew its position in shares of Galapagos by 46.8% in the first quarter. BlackRock Inc. now owns 517,611 shares of the biotechnology company’s stock valued at $32,103,000 after purchasing an additional 164,912 shares in the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Galapagos during the 4th quarter valued at $5,284,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

(Get Free Report

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.

Featured Stories